Navigation Links
Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores
Date:6/2/2008

e reimbursement for Oncotype DX through contracts, agreements and policy decisions. Both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit http://www.oncotypedx.com.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(R), which has been shown to predict the likelihood chemotherapy benefit as well as recurrence in early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's belief that the quantitative measurement of individual tumor biology is the methodology of the future and the belief that providing quantitative ER and PR scores enhances the value of Oncotype DX. These risks and uncertainties include, but are not limited to: the results of additional clinical studies; the risk that we may not obtain sufficient levels of reimbursement for any future tests we may develop; our ability to develop and commercial
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Ipsogen Launches MapQuant Dx(TM) Genomic Grade Test to Identify Breast Cancer Patients who Benefit From Chemotherapy
2. New insights into cellular reprogramming revealed by genomic analysis
3. /C O R R E C T I O N -- Rosetta Genomics Ltd/
4. Rosetta Genomics Reports First Quarter 2008 Financial Results
5. Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results
6. Albert Einstein College of Medicine Receives $25-Million Gift to Support Stem Cell and Epigenomic Research and Clinical Skills Training
7. Genomic Health Announces First Quarter 2008 Financial Results and Business Progress
8. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
9. NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008
10. Genomic Health to Announce First Quarter 2008 Financial Results and Host Conference Call on Tuesday, May 6, 2008
11. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , October 24, 2014 ... Corporation (NASDAQ: CYTR ), Vertex Pharmaceuticals Inc. ... ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... research on these five companies can be accessed at: ... Thursday, October 23, 2014, ended on a positive note ...
(Date:10/22/2014)... DUBLIN , Oct. 22, 2014 ... addition of the "Global DNA Diagnostics Market ... - Size, Share, Global Trends, Company Profiles, Demand, ... 2013 - 2020" report to their offering. ... diagnostics Market (products, applications, techniques, end users and ...
(Date:10/22/2014)... October 21, 2014 Shimadzu Scientific Instruments ... data tool for the pain management and clinical markets. ... processing and review by allowing users to highlight and ... , QuantAnalytics allows analysts to filter results by ... data processing by eliminating the need to sift through ...
(Date:10/22/2014)... 22, 2014 Grace Century, a private ... projects, announces the addition of Dr. Yousef “Josh” ... advisory team. Dr. Siddiqui will provide further healthcare expertise ... graduate of University College Medical School in ... medicine in 2001. With further certification as a General ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2
... 5:00 p.m. U.S. EDT , , FRAZER, Pa., ... quarterly earnings conference call covering second quarter 2009 results for 5:00 p.m. EDT on ... , , 4:10 p.m. EDT Q2 2009 ... To participate in the conference call, dial 913-312-0379, ...
... June 30 Hospira, Inc. (NYSE: HSP ... today announced agreements with MedAssets on intravenous (I.V.) solutions ... agreement for infusion devices. The five-year MedAssets agreements are ... and equipment, and July 1, 2009, for infusion devices. ...
... needs, clinical uses and funding sources , , ROCKVILLE, ... in Rockville, Md., announced today that former Secretary of the ... board of directors. , , "I am excited ... battlefield and in emergency rooms throughout the US. I am ...
Cached Biology Technology:Hospira Announces New Contract With MedAssets for Intravenous Solutions, Renewal of Infusion Devices Agreement 2Former Secretary of Veterans Affairs James Peake to Join the Cellphire Board of Directors 2
(Date:10/18/2014)... for evaluation of suspected genetic conditions, whole-exome sequencing ... including detection of a number of rare genetic ... to a study appearing in JAMA . ... the American Society of Human Genetics annual meeting. ... regions of thousands of genes simultaneously using next-generation ...
(Date:10/17/2014)... from the University of Copenhagen have shown for the ... lungs of Cystic fibrosis patients, giving them the opportunity ... in chronic infections. , The study also discovered the ... (CF) patients was halted or slowed down by the ... all the oxygen and helped "suffocate" the bacteria, forcing ...
(Date:10/16/2014)... Washington land managers have a new synthesis of recent ... mixed-conifer (MMC) forests in the two states. , ... Eastern Oregon and Washington: A Synthesis of the Relevant ... general technical report published by the U.S. Forest Service,s ... a request from managers for a synthesis of the ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... paradox linking artificial sweeteners such as saccharin with ... on a sweet taste has guided researchers to ... taste. , Reporting in an advance ... Chemical Senses Center describe how certain artificial sweeteners, ...
... be a key to how bacteria that infect humans ... article in the January 20 issue of the journal ... found in dirt may be the key in identifying ... infect people, predicting future clinical problems, and testing new ...
... the Kuna Indians of Panama, an international team ... is, in part, responsible, for the heart-healthy benefits ... The researchers, who are from the University of ... and Harvard Medical School, hope the findings will ...
Cached Biology News:Sweet 'water taste' paradoxically predicts sweet taste inhibitors 2Researchers use dirt to stay one step ahead of antibiotic resistance 2Researchers use dirt to stay one step ahead of antibiotic resistance 3Heart-healthy compound in chocolate identified 2
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
... has been developed for use with ... of nonspecific background staining due to ... blocking peroxidase with hydrogen peroxide. ... combination with additional novel components to ...
Rabbit polyclonal to Wilms Tumor Protein ( Abpromise for all tested applications). entrezGeneID: 7490 SwissProtID: P19544...
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: